These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12013365)

  • 21. Premature physeal closure following 13-cis-retinoic acid and prolonged fenretinide administration in neuroblastoma.
    Steineck A; MacKenzie JD; Twist CJ
    Pediatr Blood Cancer; 2016 Nov; 63(11):2050-3. PubMed ID: 27399265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
    Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.
    Veal GJ; Errington J; Redfern CP; Pearson AD; Boddy AV
    Biochem Pharmacol; 2002 Jan; 63(2):207-15. PubMed ID: 11841795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.
    Hobbie WL; Mostoufi SM; Carlson CA; Gruccio D; Ginsberg JP
    Pediatr Blood Cancer; 2011 Mar; 56(3):474-6. PubMed ID: 21072832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy?
    Padberg J; Schürmann D; Grobusch M; Bergmann F
    AIDS; 1999 Feb; 13(2):284-5. PubMed ID: 10202838
    [No Abstract]   [Full Text] [Related]  

  • 26. Isotretinoin-induced nail fragility and onycholysis.
    Onder M; Oztaş MO; Oztaş P
    J Dermatolog Treat; 2001 Jun; 12(2):115-6. PubMed ID: 12243670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats.
    Ferguson SA; Cisneros FJ; Gough B; Hanig JP; Berry KJ
    Toxicol Sci; 2005 Oct; 87(2):451-9. PubMed ID: 16033993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology.
    Bauters TG; Laureys G; Van de Velde V; Benoit Y; Robays H
    Int J Clin Pharm; 2011 Aug; 33(4):597-8. PubMed ID: 21544558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 13-cis-retinoic acid-induced eosinophilia following autologous bone marrow transplantation for neuroblastoma.
    Degar BA; Harrington RD; Rappeport JM; Woolfrey AE
    Med Pediatr Oncol; 1999 Apr; 32(4):308-10. PubMed ID: 10102029
    [No Abstract]   [Full Text] [Related]  

  • 30. 13-cis-retinoic acid-associated bone marrow edema in neuroblastoma.
    Sato Y; Kuwashima S; Kurosawa H; Sugita K; Fukushima K; Arisaka O
    Pediatr Blood Cancer; 2012 Sep; 59(3):589-90. PubMed ID: 22354520
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.
    Veal GJ; Cole M; Errington J; Pearson AD; Foot AB; Whyman G; Boddy AV;
    Br J Cancer; 2007 Feb; 96(3):424-31. PubMed ID: 17224928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sweet syndrome associated with 13-cis-retinoic acid (isotretinoin) therapy.
    Gyorfy A; Kovács T; Szegedi I; Oláh E; Kiss C
    Med Pediatr Oncol; 2003 Feb; 40(2):135-6. PubMed ID: 12461805
    [No Abstract]   [Full Text] [Related]  

  • 33. 13-cis retinoic acid and isomerisation in paediatric oncology--is changing shape the key to success?
    Armstrong JL; Redfern CP; Veal GJ
    Biochem Pharmacol; 2005 May; 69(9):1299-306. PubMed ID: 15826600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Isotretinoin embryopathy. Report of one case].
    Troncoso Sch M; Rojas H C; Bravo C E
    Rev Med Chil; 2008 Jun; 136(6):763-6. PubMed ID: 18769834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isotretinoin-induced inflammatory bowel disease.
    Passier JL; Srivastava N; van Puijenbroek EP
    Neth J Med; 2006 Feb; 64(2):52-4. PubMed ID: 16517990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.
    Veal GJ; Errington J; Rowbotham SE; Illingworth NA; Malik G; Cole M; Daly AK; Pearson AD; Boddy AV
    Clin Cancer Res; 2013 Jan; 19(2):469-79. PubMed ID: 23087409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal impairment induced by isotretinoin.
    Pavese P; Kuentz F; Belleville C; Rougé PE; Elsener M
    Nephrol Dial Transplant; 1997 Jun; 12(6):1299. PubMed ID: 9198075
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I trial of 9-cis retinoic acid in adults with solid tumors.
    Kurie JM; Lee JS; Griffin T; Lippman SM; Drum P; Thomas MP; Weber C; Bader M; Massimini G; Hong WK
    Clin Cancer Res; 1996 Feb; 2(2):287-93. PubMed ID: 9816171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
    Yung WK; Kyritsis AP; Gleason MJ; Levin VA
    Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Embryonic subcellular distribution of 13-cis- and all-trans-retinoic acid indicates differential cytosolic/nuclear localization.
    Rühl R; Plum C; Elmazar MM; Nau H
    Toxicol Sci; 2001 Sep; 63(1):82-9. PubMed ID: 11509747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.